

24 January 2022

Trial and usage of the drug cocktail 'Regen-cov'

Please Note: 'Regen-cov' closed as an arm in the Recovery Trial in July 2021 and is now available as the licenced product Ronapreve for the standard care management of COVID patients, introduced in line with UK commissioning policy. We are not able to provide information on the use of this product within the Trust, outside of the Recovery Trial, since its commissioning.

- 1. Can you advise of the full date when the Belfast health trust in Northern Ireland commenced giving the drug cocktail "Regen-cov" to acute covid 19 patients**

Under the Recovery Trial: Randomised Evaluation of COVID-19 Therapy, recruitment to the Regen-cov arm commenced 9 December 2020 in the Belfast Trust

- 2. Can you advise how many inpatients (admitted patients) have been given the drug cocktail "Regen-Cov" in the Belfast trust in particular in the Mater Hospital, Belfast**

Under the Recovery Trial, 27 admitted patients received Regen-cov in the Belfast Trust

- 3. Can you provide the safety and efficacy data from the clinical trials for "Regen-Cov"**

Safety and efficacy data for the Recovery Trial is not held by Belfast Trust. The Belfast Trust was only a participating site within the trial. Publications on the Recovery Trial are now available; alternatively this information may be available from the trial sponsor.

- 4. How many blood cancer patients, namely patients with Non Hodgkins Lymphoma and undergoing chemotherapy treatment were given the drug cocktail "Regen-Cov" in the trials**

Safety and efficacy data for the Recovery Trial is not held by Belfast Trust. The Belfast Trust was only a participating site within the trial. Publications on the Recovery Trial are now available; alternatively this information may be available from the trial sponsor.

- 5. How many blood cancer patients, namely patients with Non Hodgkins Lymphoma and undergoing chemotherapy treatment were given the**

24 January 2022

**drug cocktail "Regen-Cov" in the Belfast trust hospitals in particular the
Mater Hospital Belfast**

Nil. Under the Recovery Trial, no patients with Non Hodgkins Lymphoma and
undergoing chemotherapy treatment received Regen-cov